AKT1 and neoplasm: The in vivo anti-tumour activity of InsP5 together with the lack of toxicity observed using this compound (Maffucci et al, 2005), suggested that InsP5 might represent a lead compound to design novel inhibitors of the PI3K/Akt pathway to be eventually brought into clinical testing.